백사이트 PCVX 주가

핵심 리스크

특이 리스크 신호는 없어요 (희석·거래정지·공매도·저유통 등).

당일 등락

+45%

시가 갭

—

당일 고가 대비

—

오늘 거래정지

없음

평소 회전율 (플로트/일)

—

오늘 거래량

—

평소 회전율 = 10일 평균 거래량 ÷ 유통주식. 높을수록 손바뀜이 활발해 단타가 잘 붙어요. 오늘 거래량은 KIS 실시간이 붙으면 전체 거래소 통합, 아니면 무료 피드의 부분 집계예요(옆에 어느 쪽인지 적혀 있어요).

체결가 등락으로 매수/매도 방향을 추정한 근사치예요(tick rule). 규모는 이 종목 자체 거래 분포 기준 — 초대형 = 상위 5% 큰 체결. 최근 정규장 기준.

10일 평균 거래량

—

3개월 평균 거래량

—

발행주식수

1.5억주

유통주식 (Float)

—

52주 최고가

—

52주 최저가

—

베타

—

PER (TTM)

—

PBR

—

최근 18개월간 희석 관련 공시가 없어요.

0-100점이에요. 60점을 넘으면 스퀴즈 가능성이 있어요.

공매도 잔고 (유통 대비)

+10.8%

상환일수 (DTC)

13.0일

공매도 거래비중

+21.0%

차입 비용

+0.4%

상환일수 (DTC)

13.0일

당일 공매도 비중

21%

차입료 (CTB)

0%

대여 가능

1.0M주

• Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxivebenzinga14시간 전neutral
• 재탕Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateStockTitan14시간 전호재
• Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateGlobeNewswire어제neutral
• 재탕Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateStockTitan어제neutral
• B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130benzinga1주 전악재
• Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Targetbenzinga1주 전neutral
• Vaxcyte Narrows Timing Of Topline Data From VAX-31 Adult Phase 3 OPUS-1 Trial To End Of October 2026 From Q4 2026benzinga2026.09.04 05:12neutral
• Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga1주 전neutral

1. 뉴스14시간 전 · benzinga

   Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxive

2. 뉴스14시간 전 · StockTitan

   Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

3. 뉴스어제 · GlobeNewswire

   Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

4. 뉴스어제 · StockTitan

   Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

5. 뉴스1주 전 · benzinga

   B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130

6. 뉴스1주 전 · benzinga

   Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Target

7. 뉴스2026.09.04 05:12 · benzinga

   Vaxcyte Narrows Timing Of Topline Data From VAX-31 Adult Phase 3 OPUS-1 Trial To End Of October 2026 From Q4 2026

8. 뉴스1주 전 · benzinga

   Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday

불러오는 중…

분류

분류·메모를 달면 자동으로 관심종목에 담겨요.

불러오는 중…